A. W. Tai and R. T. Chung, Treatment failure in hepatitis C: Mechanisms of non-response, Journal of Hepatology, vol.50, issue.2
DOI : 10.1016/j.jhep.2008.11.010

C. Hezode, Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection, New England Journal of Medicine, vol.360, issue.18, pp.1839-1850, 2009.
DOI : 10.1056/NEJMoa0807650

URL : https://hal.archives-ouvertes.fr/inserm-00385235

J. M. Timpe, Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies, Hepatology, vol.7, issue.1, pp.17-24, 2008.
DOI : 10.1002/hep.21959

M. B. Zeisel, F. L. Cosset, and T. Baumert, Host neutralizing responses and pathogenesis of hepatitis C virus infection, Hepatology, vol.5, issue.1, pp.299-307, 2008.
DOI : 10.1002/hep.22307

URL : https://hal.archives-ouvertes.fr/inserm-00395783

T. Von-hahn and C. M. Rice, Hepatitis C Virus Entry, Journal of Biological Chemistry, vol.283, issue.7, pp.3689-3693, 2008.
DOI : 10.1074/jbc.R700024200

H. Barth, Viral and Cellular Determinants of the Hepatitis C Virus Envelope-Heparan Sulfate Interaction, Journal of Virology, vol.80, issue.21, pp.10579-10590, 2006.
DOI : 10.1128/JVI.00941-06

P. Pileri, Binding of Hepatitis C Virus to CD81, Science, vol.282, issue.5390, pp.938-941, 1998.
DOI : 10.1126/science.282.5390.938

E. Scarselli, The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus, The EMBO Journal, vol.269, issue.19, pp.5017-5025, 2002.
DOI : 10.1093/emboj/cdf529

M. J. Evans, Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry, Nature, vol.23, issue.7137, pp.801-805, 2007.
DOI : 10.1038/nature05654

A. Ploss, Human occludin is a hepatitis C virus entry factor required for infection of mouse cells, Nature, vol.309, issue.7231, pp.882-886, 2009.
DOI : 10.1038/nature07684

M. Hidalgo and D. Bloedow, Pharmacokinetics and pharmacodynamics: Maximizing the clinical potential of Erlotinib (Tarceva), Seminars in Oncology, vol.30, issue.3, pp.25-33, 2003.
DOI : 10.1016/S0093-7754(03)70012-8

F. A. Shepherd, Erlotinib in Previously Treated Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.353, issue.2
DOI : 10.1056/NEJMoa050753

J. Li, A chemical and phosphoproteomic characterization of dasatinib action in lung cancer, Nature Chemical Biology, vol.14, issue.4, pp.291-299, 2010.
DOI : 10.1038/nchembio.332

S. Fafi-kremer, Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation, The Journal of Experimental Medicine, vol.119, issue.9, pp.2019-2031, 2010.
DOI : 10.1073/pnas.0503596102

C. J. Mee, Polarization Restricts Hepatitis C Virus Entry into HepG2 Hepatoma Cells, Journal of Virology, vol.83, issue.12
DOI : 10.1128/JVI.00246-09

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687400

J. Schlessinger, Ligand-Induced, Receptor-Mediated Dimerization and Activation of EGF Receptor, Cell, vol.110, issue.6, pp.669-672, 2002.
DOI : 10.1016/S0092-8674(02)00966-2

G. H. Thoresen, Response to transforming growth factor ?? (TGF??) and epidermal growth factor (EGF) in hepatocytes: Lower EGF receptor affinity of TGF?? is associated with more sustained activation of p42/p44 mitogen-activated protein kinase and greater efficacy in stimulation of DNA synthesis, Journal of Cellular Physiology, vol.60, issue.1, pp.10-18, 1998.
DOI : 10.1002/(SICI)1097-4652(199804)175:1<10::AID-JCP2>3.0.CO;2-F

M. Dreux, Receptor Complementation and Mutagenesis Reveal SR-BI as an Essential HCV Entry Factor and Functionally Imply Its Intra- and Extra-Cellular Domains, PLoS Pathogens, vol.100, issue.2, p.1000310, 2009.
DOI : 10.1371/journal.ppat.1000310.s005

URL : http://doi.org/10.1371/journal.ppat.1000310

S. E. Krieger, Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-Claudin-1 associations, Hepatology, vol.79, issue.4, pp.1144-1157, 2010.
DOI : 10.1002/hep.23445

URL : https://hal.archives-ouvertes.fr/inserm-00705657

G. Koutsoudakis, Characterization of the Early Steps of Hepatitis C Virus Infection by Using Luciferase Reporter Viruses, Journal of Virology, vol.80, issue.11, pp.5308-5320, 2006.
DOI : 10.1128/JVI.02460-05

M. B. Zeisel, Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81, Hepatology, vol.279, issue.6, pp.1722-1731, 2007.
DOI : 10.1002/hep.21994

URL : https://hal.archives-ouvertes.fr/inserm-00395706

M. Dreux, High Density Lipoprotein Inhibits Hepatitis C Virus-neutralizing Antibodies by Stimulating Cell Entry via Activation of the Scavenger Receptor BI, Journal of Biological Chemistry, vol.281, issue.27
DOI : 10.1074/jbc.M602706200

URL : https://hal.archives-ouvertes.fr/hal-00313930

H. J. Harris, Claudin Association with CD81 Defines Hepatitis C Virus Entry, Journal of Biological Chemistry, vol.285, issue.27
DOI : 10.1074/jbc.M110.104836

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2898367

H. J. Harris, CD81 and Claudin 1 Coreceptor Association: Role in Hepatitis C Virus Entry, Journal of Virology, vol.82, issue.10, pp.5007-5020, 2008.
DOI : 10.1128/JVI.02286-07

D. Lavillette, Characterization of Fusion Determinants Points to the Involvement of Three Discrete Regions of Both E1 and E2 Glycoproteins in the Membrane Fusion Process of Hepatitis C Virus, Journal of Virology, vol.81, issue.16, pp.8752-8765, 2007.
DOI : 10.1128/JVI.02642-06

J. Witteveldt, CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells, Journal of General Virology, vol.90, issue.1, pp.48-58, 2009.
DOI : 10.1099/vir.0.006700-0

N. Hiraga, Absence of viral interference and different susceptibility to interferon between hepatitis B virus and hepatitis C virus in human hepatocyte chimeric mice, Journal of Hepatology, vol.51, issue.6
DOI : 10.1016/j.jhep.2009.09.002

N. Kamiya, Practical evaluation of a mouse with chimeric human liver model for hepatitis C virus infection using an NS3-4A protease inhibitor, Journal of General Virology, vol.91, issue.7, pp.1668-1677, 2010.
DOI : 10.1099/vir.0.019315-0

P. Meuleman, Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera, Hepatology, vol.158, issue.4, pp.847-856, 2005.
DOI : 10.1002/hep.20657

B. Higgins, Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models, Anti-Cancer Drugs, vol.15, issue.5, pp.503-512, 2004.
DOI : 10.1097/01.cad.0000127664.66472.60

M. R. Schneider and E. Wolf, The epidermal growth factor receptor ligands at a glance, Journal of Cellular Physiology, vol.282, issue.3, pp.460-466, 2009.
DOI : 10.1002/jcp.21635

M. Lackmann and A. W. Boyd, Eph, a Protein Family Coming of Age: More Confusion, Insight, or Complexity?, Science Signaling, vol.1, issue.15, p.2, 2008.
DOI : 10.1126/stke.115re2

A. B. Singh and R. C. Harris, Epidermal Growth Factor Receptor Activation Differentially Regulates Claudin Expression and Enhances Transepithelial Resistance in Madin-Darby Canine Kidney Cells, Journal of Biological Chemistry, vol.279, issue.5, pp.3543-3552, 2004.
DOI : 10.1074/jbc.M308682200

D. Flores-benitez, Control of tight junctional sealing: roles of epidermal growth factor and prostaglandin E2, AJP: Cell Physiology, vol.297, issue.3, pp.611-620, 2009.
DOI : 10.1152/ajpcell.00622.2008

E. Blanchard, Hepatitis C Virus Entry Depends on Clathrin-Mediated Endocytosis, Journal of Virology, vol.80, issue.14
DOI : 10.1128/JVI.00024-06

URL : https://hal.archives-ouvertes.fr/hal-00105504

J. L. Reiter and N. J. Maihle, A 1.8 kb alternative transcript from the human epidermal growth factor receptor gene encodes a truncated form of the receptor, Nucleic Acids Research, vol.24, issue.20, pp.4050-4056, 1996.
DOI : 10.1093/nar/24.20.4050

URL : https://hal.archives-ouvertes.fr/in2p3-00024414

D. F. Mccole, S. J. Keely, R. J. Coffey, and K. E. Barrett, Transactivation of the Epidermal Growth Factor Receptor in Colonic Epithelial Cells by Carbachol Requires Extracellular Release of Transforming Growth Factor-alpha, Journal of Biological Chemistry, vol.277, issue.45, pp.42603-42612, 2002.
DOI : 10.1074/jbc.M206487200

H. Miao, EphA2 Mediates Ligand-Dependent Inhibition and Ligand-Independent Promotion of Cell Migration and Invasion via a Reciprocal Regulatory Loop with Akt, Cancer Cell, vol.16, issue.1, pp.9-20, 2009.
DOI : 10.1016/j.ccr.2009.04.009

J. M. Pestka, Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C, Proceedings of the National Academy of Sciences, vol.104, issue.14, pp.6025-6030, 2007.
DOI : 10.1073/pnas.0607026104

URL : https://hal.archives-ouvertes.fr/inserm-00395910

S. M. Rothenberg, Modeling oncogene addiction using RNA interference, Proceedings of the National Academy of Sciences, vol.105, issue.34
DOI : 10.1073/pnas.0803217105

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2517605

B. Bartosch, J. Dubuisson, and F. L. Cosset, Infectious Hepatitis C Virus Pseudo-particles Containing Functional E1???E2 Envelope Protein Complexes, The Journal of Experimental Medicine, vol.72, issue.5, pp.633-642, 2003.
DOI : 10.1093/emboj/21.12.2893

URL : https://hal.archives-ouvertes.fr/inserm-00133783

T. Pietschmann, Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras, Proceedings of the National Academy of Sciences, vol.103, issue.19, pp.7408-7413, 2006.
DOI : 10.1073/pnas.0504877103

D. Lavillette, Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus, Hepatology, vol.82, issue.2, pp.265-274, 2005.
DOI : 10.1002/hep.20542

C. Frecha, Efficient and stable transduction of resting B lymphocytes and primary chronic lymphocyte leukemia cells using measles virus gp displaying lentiviral vectors, Blood, vol.114, issue.15, pp.3173-3180, 2009.
DOI : 10.1182/blood-2009-05-220798

V. Sandrin, Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates, Blood, vol.100, issue.3, pp.823-832, 2002.
DOI : 10.1182/blood-2001-11-0042

I. Fofana, Monoclonal Anti-Claudin 1 Antibodies Prevent Hepatitis C Virus Infection of Primary Human Hepatocytes, Gastroenterology, vol.139, issue.3, pp.953-964, 2010.
DOI : 10.1053/j.gastro.2010.05.073

URL : https://hal.archives-ouvertes.fr/inserm-00741442

J. C. Meunier, Isolation and Characterization of Broadly Neutralizing Human Monoclonal Antibodies to the E1 Glycoprotein of Hepatitis C Virus, Journal of Virology, vol.82, issue.2, pp.966-973, 2008.
DOI : 10.1128/JVI.01872-07

V. Lohmann, Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell Line, Science, vol.285, issue.5424, pp.110-113, 1999.
DOI : 10.1126/science.285.5424.110

S. Van-den-heuvel and E. Harlow, Distinct roles for cyclin-dependent kinases in cell cycle control, Science, vol.262, issue.5142, pp.2050-2054, 1993.
DOI : 10.1126/science.8266103

Y. Wang, Negative regulation of EphA2 receptor by Cbl, Biochemical and Biophysical Research Communications, vol.296, issue.1
DOI : 10.1016/S0006-291X(02)00806-9

A. Chahbouni, J. C. Den-burger, R. M. Vos, A. Sinjewel, and A. J. Wilhelm, Simultaneous quantification of erlotinib, gefitinib, and imatinib in human plasma by liquid chromatography tandem mass spectrometry, Ther. Drug Monit, vol.31, pp.683-687, 2009.

T. Mosmann, Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays, Journal of Immunological Methods, vol.65, issue.1-2, pp.55-63, 1983.
DOI : 10.1016/0022-1759(83)90303-4